Burixafor clinical trials
Also written TG-0054.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses burixafor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2008 (1)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
GPCR Therapeutics, Inc. (4)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses burixafor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy VolunteersCompletedPhase 1GPCR Therapeutics, Inc.NCT00822341Written as TG-0054How we know
- Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease PatientsCompletedPhase 2GPCR Therapeutics, Inc.NCT01018979Written as TG-0054 (2.24 mg/kg)How we know
- PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease PatientsCompletedPhase 2GPCR Therapeutics, Inc.NCT02104427Written as TG-0054 combined with G-CSFHow we know
- A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin DiseaseCompletedPhase 2GPCR Therapeutics, Inc.NCT01458288Written as TG-0054How we know
As the comparator · 1 — what is tested is compared with burixafor
Codes
What other systems call burixafor · ClinicalTrials.gg INT014473
- UNII (FDA) 2G17Y0Q20GBURIXAFORConfirmed FDA, Wikidata
- Wikidata Q27254687burixaforConfirmed FDA, Wikidata
- NCI Thesaurus C88323BurixaforOne source FDA
- DrugBank DB11970One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2G17Y0Q20G | BURIXAFOR | Confirmed FDA, Wikidata |
| Wikidata | Q27254687 | burixafor | Confirmed FDA, Wikidata |
| NCI Thesaurus | C88323 | Burixafor | One source FDA |
| DrugBank | DB11970 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.